Stock Rating Report for AMRI

Ticker: 

Stock Information

Ticker AMRI
Company Name Albany Molecular Research Inc
Current Price $3.00
Previous Close $3.00
Industry Biotechnology
Sector HEALTHCARE
Long Stop Loss Members Only
Short Stop Loss Members Only
Expected Move Members Only
Optionable? Yes

StockProphet Ratings

Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.

Sector Risks

Sign up for MarketProphet today to see our 30, 60, and 90 day risk assessment for this stock.


Chart

We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for AMRI. However, we only show it to our subscribers.

We update our ratings and stop losses EVERY WEEK.

Don't miss out on what we recommend for Albany Molecular Research Inc next week. Sign up today and start making money!

Demand Fundamentals

Demand Fundamental Value Score Rating
Qtr/Qtr Revenue Growth Members Only
Qtr/Qtr Earnings Growth Members Only
Year/Year Revenue Growth Members Only
Year/Year Earnings Growth Members Only
Multi-Year Revenue Growth Members Only
Multi-Year Earnings Growth Members Only
Relative PE Ranking Members Only
Return on Equity Members Only
Yield Members Only
Institutional Holding Members Only
Stock Price Members Only
Relative Fundamental Ranking Members Only
Total Score Members Only

Demand Technicals

Demand Technical Value Score Rating
Recommended Condition Members Only
Trading Zone Members Only
Average Trading Volume Members Only
Industry Bull/Bear Condition Members Only
Sector Bull/Bear Condition Members Only
Current Signal Start Date Members Only
Total Score Members Only

Company Profile

Albany Molecular Research, Inc. provides contract services to various pharmaceutical and biotechnology companies primarily in the United States, Europe, and Asia. The company offers a range of drug discovery services, including assay development and design, screening, screening library, natural product, medicinal chemistry, computer-aided drug discovery, in vitro ADMET, and bioanalytical services. It also provides chemical development services consisting of process research and development, custom synthesis, process safety assessment, scale-up capabilities, high potency and controlled substances, analytical services, preformulation services and physical characterization, preparative chromatography, IND support services, fermentation development and optimization, and building blocks collection and database services. In addition, the company offers chemical synthesis and manufacturing services. It manufactures active pharmaceutical ingredients (APIs)and advanced intermediates. Further, the company provides contract manufacturing services in sterile syringe and vial filling for small molecule drug products and biologicals. Additionally, it offers formulation services, including neat API or pharmaceutical blend in capsules- PIB for solution and suspension- blending and sieving- milling- tableting- rheology- roller compaction- wet granulation- and fluid bed processing, including wurster coating- and associated analytical testing services for dosage formulation products, as well as provides analytical services, such as impurity identification and structure elucidation- method development, qualification, and validation- preformulation and physical characterization- quality control- stability services- analytical and preparative supercritical fluid chromatography- preparative chromatography- good laboratory practices bioanalytical services- and regulatory support/quality assurance services. The company was founded in 1991 and is based in Albany, New York.


Latest News

Tue, 07 Feb 2012 22:03:53 GMTALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
Tue, 07 Feb 2012 17:08:28 GMTAMRI reports net loss of $32M in 2011
Tue, 07 Feb 2012 13:14:29 GMTDIARY-U.S. MEETINGS/WEEK AHEAD
Tue, 07 Feb 2012 13:00:00 GMTAMRI Announces Fourth Quarter and Full Year 2011 Results
Tue, 07 Feb 2012 12:07:20 GMTQ4 2011 Albany Molecular Research Inc Earnings Release - Before Market Open
Mon, 06 Feb 2012 13:37:19 GMTDIARY-U.S. MEETINGS/WEEK AHEAD
Fri, 03 Feb 2012 12:01:15 GMTDIARY-U.S. MEETINGS/WEEK AHEAD
Thu, 02 Feb 2012 14:32:28 GMTDIARY-U.S. MEETINGS/WEEK AHEAD
Wed, 01 Feb 2012 13:00:00 GMTAMRI CFO to Present at UBS 22nd Annual Global Healthcare Services Conference
Tue, 31 Jan 2012 13:00:00 GMTAMRI to Announce Fourth Quarter Results
Wed, 18 Jan 2012 13:05:14 GMTAlbany Molecular U.K. facility gets MHRA GMP certification
Wed, 18 Jan 2012 13:00:00 GMTMHRA Issues GMP Certification to AMRI UK Facility
Mon, 09 Jan 2012 13:00:00 GMTAMRI Announces Review of Its Hungary Operation
Thu, 05 Jan 2012 13:00:00 GMTAMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC
Fri, 23 Dec 2011 11:50:21 GMTStocks to watch Friday: Shutterfly, Rambus, CIT
Thu, 22 Dec 2011 22:39:50 GMTUPDATE 1-Albany Molecular cuts jobs in Q4
Thu, 22 Dec 2011 22:15:00 GMTAMRI Announces Additional Actions to Streamline Operations
Thu, 22 Dec 2011 21:58:40 GMTALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Regulation FD Di
Mon, 05 Dec 2011 21:57:04 GMTALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi
Fri, 10 Jun 2011 07:06:00 GMTTyraTech, Inc. - Preliminary Results
News provided by Yahoo! Finance